Zheng Y, Yuan J, Woods C, Machtay M, Wessels B
University Hospitals Case Medical Center, Cleveland, OH.
Med Phys. 2012 Jun;39(6Part17):3810-3811. doi: 10.1118/1.4735549.
Direct addition of doses between plans with different fractionation fails to provide accurate dose-response information to anticipate clinical outcome. To combine different fractionation patterns, first-order biological model correction for dose-rate must be included. Moreover, 3-D isoeffect patterns of the combined doses must be displayed so that overlap area to elegant volumes can be avoided. The linear quadratic (LQ) model and biologically effective dose (BED) method were used to produce a combined plan in equivalent 2 Gy fractions (EQD2) for radiosurgery and conventional 3D radiotherapy.
For patients with multiple courses of radiotherapy, dose distributions of the prior and boost treatment plans were converted to BED. The fraction size specified by the prescription was applied globally for each BED calculation, α/β ratio of 10 and 2.5 was used for early and late effect, respectively. Image registration with CT or MR was performed for initial and boost plans. The registration information was applied to dose distributions to obtain the composite EQD2.
As a demonstration of this method, two patients were selected who had combined treatments from substantially different modalities. A patient with liver cancer initially received radiotherapy of 30 Gy/10 Fx and re-irradiation with CyberKnife radiosurgery (15 Gy/1 Fx). The combined plan showed that the PTV received EQD2 of 63.8 Gy. Another patient had brain metastasis treated with GammaKnife of 18 Gy (50% isodose) followed by conventional 3D whole brain radiation of 30 Gy/10 Fx. The minimal combined tumor EQD2 was 74.5 Gy. Early and late calculated responses showed that all critical organ doses were within tolerance.
For patients receiving radiation with different fractionation schemes, combined isoeffective dose distributions were calculated and displayed. In both cases, crucial information regarding 3-D dose distributions assisted the physicians in determining whether tolerance limits of overlap areas of retreated critical structures were preserved.
直接将不同分割方案的计划剂量相加,无法提供准确的剂量反应信息以预测临床结果。为了合并不同的分割模式,必须纳入剂量率的一阶生物学模型校正。此外,必须显示合并剂量的三维等效效应模式,以便避免与靶区的重叠区域。采用线性二次(LQ)模型和生物等效剂量(BED)方法,生成适用于立体定向放射治疗和传统三维放射治疗的等效2 Gy分割(EQD2)的合并计划。
对于接受多程放疗的患者,将先前治疗计划和加量治疗计划的剂量分布转换为BED。在每次BED计算中全局应用处方规定的分割大小,早期效应和晚期效应分别采用α/β比值10和2.5。对初始计划和加量计划进行CT或MR图像配准。将配准信息应用于剂量分布以获得复合EQD2。
作为该方法的示例,选择了两名接受了截然不同治疗方式联合治疗的患者。一名肝癌患者最初接受了30 Gy/10次分割的放疗,随后接受了射波刀立体定向放射治疗(15 Gy/1次分割)。合并计划显示,计划靶体积(PTV)接受的EQD2为63.8 Gy。另一名脑转移患者先接受了伽玛刀18 Gy(50%等剂量线)治疗,随后接受了30 Gy/10次分割的传统三维全脑放疗。合并后的肿瘤最小EQD2为74.5 Gy。早期和晚期计算的反应表明,所有关键器官剂量均在耐受范围内。
对于接受不同分割方案放疗的患者,计算并显示了合并的等效效应剂量分布。在这两个病例中,关于三维剂量分布的关键信息有助于医生确定再次治疗的关键结构重叠区域的耐受限度是否得到保留。